The move takes place one day after the country’s national drug regulator Anvisa approved the administration of CoronaVac in children and adolescents aged six through 17.
Anvisa says that, for the inclusion of new audiences in the package insert, it is necessary for the laboratory to carry out studies on the relationship of safety and efficacy for "a certain age group".
Responsible for CoronaVac, Sinovac laboratory is developing a specific vaccine for Ômicron and says that its immunizing agent is effective against this variant of the coronavirus.
Study found 99% of vaccinated people in Serrana seroconverted.The indicator was higher than the results from the clinical trials from phases one and two of CoronaVac, showing seroconversion at around 97 and 98 percent, respectively, depending on the dose.
“The immunogenicity data leave uncertainties regarding how long the protection provided by the inoculation lasts,” Anvisa stated in a note.
Português 
Español 
